ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.45 Billion KRW | 0.0% |
| 2022 | 1.45 Billion KRW | 138.43% |
| 2021 | -3.78 Billion KRW | -303.32% |
| 2020 | 1.85 Billion KRW | 116.53% |
| 2019 | -11.24 Billion KRW | -11.12% |
| 2018 | -10.12 Billion KRW | -54.26% |
| 2017 | -6.56 Billion KRW | 29.34% |
| 2016 | -9.28 Billion KRW | -8438.81% |
| 2015 | 111.38 Million KRW | -87.68% |
| 2014 | 903.98 Million KRW | 150.27% |
| 2013 | -1.79 Billion KRW | -151.45% |
| 2012 | 3.49 Billion KRW | 133.79% |
| 2011 | -10.34 Billion KRW | -245.77% |
| 2010 | -2.99 Billion KRW | -26.61% |
| 2009 | -2.36 Billion KRW | -209.29% |
| 2008 | 2.16 Billion KRW | -17.94% |
| 2007 | 2.63 Billion KRW | 127.89% |
| 2006 | 1.15 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 372.99 Million KRW | 83.71% |
| 2023 Q4 | -409.99 Million KRW | 17.63% |
| 2023 Q3 | -497.74 Million KRW | -10715.67% |
| 2023 FY | 1.45 Billion KRW | 0.0% |
| 2023 Q1 | 690.09 Million KRW | 111.52% |
| 2023 Q2 | -4.6 Million KRW | -100.67% |
| 2022 Q2 | -180.01 Million KRW | -118.82% |
| 2022 FY | 1.45 Billion KRW | 138.43% |
| 2022 Q4 | 326.25 Million KRW | -6.79% |
| 2022 Q3 | 350.01 Million KRW | 294.44% |
| 2022 Q1 | 956.54 Million KRW | 0.0% |
| 2021 Q3 | 1.01 Billion KRW | 364.59% |
| 2021 FY | -3.78 Billion KRW | -303.32% |
| 2021 Q1 | 657.72 Million KRW | -41.82% |
| 2021 Q2 | -383.07 Million KRW | -158.24% |
| 2020 Q4 | 1.13 Billion KRW | -19.76% |
| 2020 FY | 1.85 Billion KRW | 116.53% |
| 2020 Q1 | -117.75 Million KRW | 92.38% |
| 2020 Q2 | -562.22 Million KRW | -377.44% |
| 2020 Q3 | 1.4 Billion KRW | 350.61% |
| 2019 Q1 | -2.26 Billion KRW | 22.69% |
| 2019 FY | -11.24 Billion KRW | -11.12% |
| 2019 Q3 | -498.06 Million KRW | 92.83% |
| 2019 Q2 | -6.94 Billion KRW | -206.98% |
| 2019 Q4 | -1.54 Billion KRW | -210.33% |
| 2018 FY | -10.12 Billion KRW | -54.26% |
| 2018 Q3 | -3.22 Billion KRW | -22.71% |
| 2018 Q4 | -2.92 Billion KRW | 9.41% |
| 2018 Q1 | -1.33 Billion KRW | 44.59% |
| 2018 Q2 | -2.63 Billion KRW | -96.89% |
| 2017 FY | -6.56 Billion KRW | 29.34% |
| 2017 Q2 | -878.53 Million KRW | 61.84% |
| 2017 Q3 | -969.75 Million KRW | -10.38% |
| 2017 Q1 | -2.3 Billion KRW | -43.87% |
| 2017 Q4 | -2.41 Billion KRW | -148.75% |
| 2016 FY | -9.28 Billion KRW | -8438.81% |
| 2016 Q2 | -2.36 Billion KRW | 4.83% |
| 2016 Q3 | -2.84 Billion KRW | -20.62% |
| 2016 Q4 | -1.6 Billion KRW | 43.8% |
| 2016 Q1 | -2.48 Billion KRW | -294.68% |
| 2015 Q1 | 98.86 Million KRW | 124.82% |
| 2015 Q4 | -628.41 Million KRW | -191.66% |
| 2015 Q3 | 685.61 Million KRW | 1634.33% |
| 2015 FY | 111.38 Million KRW | -87.68% |
| 2015 Q2 | -44.68 Million KRW | -145.2% |
| 2014 Q3 | 26.65 Million KRW | -96.37% |
| 2014 Q1 | 529.5 Million KRW | 140.1% |
| 2014 FY | 903.98 Million KRW | 150.27% |
| 2014 Q2 | 735.27 Million KRW | 38.86% |
| 2014 Q4 | -398.35 Million KRW | -1594.47% |
| 2013 Q2 | -1.05 Billion KRW | -315.19% |
| 2013 FY | -1.79 Billion KRW | -151.45% |
| 2013 Q4 | -1.32 Billion KRW | -258.62% |
| 2013 Q3 | 832.44 Million KRW | 178.84% |
| 2013 Q1 | -254.3 Million KRW | -147.11% |
| 2012 FY | 3.49 Billion KRW | 133.79% |
| 2012 Q2 | -85.67 Million KRW | -104.87% |
| 2012 Q3 | 1.28 Billion KRW | 1596.4% |
| 2012 Q4 | 539.87 Million KRW | -57.89% |
| 2012 Q1 | 1.75 Billion KRW | 0.0% |
| 2011 Q3 | 213.1 Million KRW | 102.07% |
| 2011 Q2 | -10.3 Billion KRW | -4330.75% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q1 | 243.63 Million KRW | 0.0% |
| 2011 FY | -10.34 Billion KRW | -245.77% |
| 2010 Q4 | - KRW | 100.0% |
| 2010 Q1 | 504.56 Million KRW | 0.0% |
| 2010 Q2 | -745.24 Million KRW | -247.7% |
| 2010 Q3 | -386.44 Million KRW | 48.15% |
| 2010 FY | -2.99 Billion KRW | -26.61% |
| 2009 Q1 | 323.62 Million KRW | 0.0% |
| 2009 Q2 | 249.44 Million KRW | -22.92% |
| 2009 Q3 | 91.99 Million KRW | -63.12% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | -2.36 Billion KRW | -209.29% |
| 2008 Q1 | 476.36 Million KRW | 0.0% |
| 2008 Q3 | 195.01 Million KRW | -78.2% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | 2.16 Billion KRW | -17.94% |
| 2008 Q2 | 894.62 Million KRW | 87.8% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 2.63 Billion KRW | 127.89% |
| 2007 Q1 | 94.75 Million KRW | 0.0% |
| 2007 Q3 | 357.49 Million KRW | 1702.44% |
| 2007 Q2 | 19.83 Million KRW | -79.07% |
| 2006 FY | 1.15 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Green Cross Holdings Corporation | -16.43 Billion KRW | 108.838% |
| Green Cross Holdings Corporation | 34.43 Billion KRW | 95.781% |
| Pharmicell Co., Ltd. | 950.99 Million KRW | -52.767% |
| Green Cross Corporation | 34.43 Billion KRW | 95.781% |
| GeneOne Life Science, Inc. | -48.36 Billion KRW | 103.004% |
| Celltrion, Inc. | 651.43 Billion KRW | 99.777% |
| Samsung Biologics Co.,Ltd. | 1155.98 Billion KRW | 99.874% |
| SK bioscience Co.,Ltd. | -4.73 Billion KRW | 130.708% |
| SK Biopharmaceuticals Co., Ltd. | -37.52 Billion KRW | 103.872% |
| Prestige BioPharma Limited | -62.78 Billion KRW | 102.314% |